前入路机器人辅助根治性前列腺切除术后的阳性手术切缘:多机构合作中评估学习曲线
该多机构研究分析了2003至2022年间欧洲和北美十家机构74名外科医生实施的13090例机器人辅助根治性前列腺切除术,评估外科医生经验与阳性手术切缘的关系。调整病例组合后,手术经验与阳性切缘概率呈显著非线性关联,经验越多风险越低,概率从10例前的26%降至2000例前的14%,约在第500例时趋于平台。
要点
- 共13090例患者中2838例(22%)最终病理显示阳性手术切缘。
- 调整病例组合后,手术经验与阳性切缘概率呈显著非线性关联(p < 0.0001)。
- 外科医生既往机器人手术量为10、250、500、2000例时,阳性切缘概率分别为26%、21%、18%、14%,约在第500例时趋于平台。
核心结论
- 研究描述了机器人辅助根治性前列腺切除术后阳性切缘的学习曲线,但手术学习对达到最佳结局的相对贡献仍存争议。
- 未来研究应关注有经验的外科医生如何避免阳性切缘,并探索学习、切缘率与生化复发之间的关系。
研究设计与样本
- 多机构合作分析,纳入2003至2022年间欧洲和北美十家机构74名外科医生实施的13090例机器人辅助根治性前列腺切除术的前列腺癌患者数据。
- 采用多变量模型评估每例患者手术时外科医生经验与术后阳性切缘的关联,并调整术前前列腺特异性抗原水平、分级、分期和手术年份。
- 外科医生经验编码为在索引患者手术前该外科医生完成的机器人根治性前列腺切除术例数。
主要发现
- 总体2838例(22%)男性最终病理显示阳性手术切缘。
- 调整病例组合后,手术经验与术后阳性切缘概率呈显著非线性关联,经验越多阳性切缘风险越低(p < 0.0001)。
- 外科医生既往机器人手术量为10、250、500、2000例时,患者阳性切缘概率分别为26%、21%、18%、14%;10例与2000例之间的绝对风险差为11%(95%CI:9%,14%)。
- 按最终病理囊外扩展分层分析得到相似结果;排除在机构间流动的外科医生后结果亦未改变。
临床怎么用
- 患者总结指出,接受机器人根治性前列腺切除术的前列腺癌患者中,阳性手术切缘风险随经验增加而逐步降低,约在第500例手术时趋于平台。
局限性
- 手术学习对达到最佳结局的相对贡献仍存争议。
- 未来研究应关注有经验的外科医生如何避免阳性切缘,并探索学习、切缘率与生化复发之间的关系。
- 理解哪些切缘影响复发以及这些切缘是否可训练或由其他因素导致,可能揭示未来外科教育应聚焦何处。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The learning curve for robot-assisted radical prostatectomy (RARP) remains controversial, with prior studies showing that, in contrast with evidence on open and laparoscopic radical prostatectomy, biochemical recurrence rates of experienced versus inexperienced surgeons did not differ. OBJECTIVE: To characterize the learning curve for positive surgical margins (PSMs) after RARP. DESIGN, SETTING, AND PARTICIPANTS: We analyzed the data of 13 090 patients with prostate cancer undergoing RARP by one of 74 surgeons from ten institutions in Europe and North America between 2003 and 2022. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable models were used to assess the association between surgeon experience at the time of each patient's operation and PSMs after surgery, with adjustment for preoperative prostate-specific antigen level, grade, stage, and year of surgery. Surgeon experience was coded as the number of robotic radical prostatectomies done by the surgeon before the index patient's operation. RESULTS AND LIMITATIONS: Overall, 2838 (22%) men had PSMs on final pathology. After adjusting for case mix, we found a significant, nonlinear association between surgical experience and probability of PSMs after surgery, with a lower risk of PSMs for greater surgeon experience (p < 0.0001). The probabilities of PSMs for a patient treated by a surgeon with ten, 250, 500, and 2000 prior robotic procedures were 26%, 21%, 18%, and 14%, respectively (absolute risk difference between ten and 2000 procedures: 11%; 95% confidence interval: 9%, 14%). Similar results were found after stratifying patients according to extracapsular extension at final pathology. Results were also unaltered after excluding surgeons who had moved between institutions. CONCLUSIONS: While we characterized the learning curve for PSMs after RARP, the relative contribution of surgical learning to the achievement of optimal outcomes remains controversial. Future investigations should focus on what experienced surgeons do to avoid positive margins and should explore the relationship between learning, margin rate, and biochemical recurrence. Understanding what margins affect recurrence and whether these margins are trainable or a result of other factors may shed light on where to focus future efforts in surgical education. PATIENT SUMMARY: In patients receiving robotic radical prostatectomy for prostate cancer, we characterized the learning curve for positive margins. The risk of surgical margins decreased progressively with increasing experience, and plateaued around the 500th procedure. Understanding what margins affect recurrence and whether these margins are trainable or a result of other factors has implications for surgeons and patients, and it may shed light on where to focus future efforts in surgical education.
引用
- Bravi CA, Dell'Oglio P, Piazza P, et al. Positive Surgical Margins After Anterior Robot-assisted Radical Prostatectomy: Assessing the Learning Curve in a Multi-institutional Collaboration. Eur Urol Oncol. 2023. PMID: 38036328. doi:10.1016/j.euo.2023.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。